Swedish doctors debate best practices for prescribing diabetes drug GLP-1

A research team has responded to criticism of their study on how doctors in Stockholm prescribe GLP-1 receptor agonists, the blockbuster weight-loss and diabetes drugs now reshaping healthcare costs. The exchange highlights ongoing confusion about optimal prescribing patterns as demand for these medications surges across Europe.

Originaltitel: Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper "prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study"